![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tirofiban Hydrochloride-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia.
Lead Product(s): Tirofiban,Clopidogrel,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.
Lead Product(s): Tirofiban,Prasugrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hong Kong Teson Pharma
Deal Size: $3.5 million Upfront Cash: $3.0 million
Deal Type: Agreement March 10, 2020